Clinical trial of tepoxalin use in cranial cruciate ligament rupture conservative treatment in dogs

Abstract

The rupture of the cranial cruciate ligament (CCLR) characterizes itself for a partial or a total laceration of the cranial cruciate ligament. Patients with ligament (partial or total) acute laceration present acute lameness, with total or partial incapacity of sustentation of their weight on the affected leg. The clinic therapy with conservative drugs must be used previously to the surgical treatment. The tepoxalin, a no steroid anti-inflammatory can be indicate in the reduction of the inflammatory process and relieve of the pain, caused by acute and chronic musculoskeletal disturbances. It promotes a balanced blockade of the brake of the arachidonic acid by the lipoxygenase and cycloxigenase rote of the inflammatory cascade. Thus, the purpose of this study was to evaluate the tepoxalin efficiency in CCLR conservative treatment, though specific clinical test, radiographic exams, and cytological analysis of the articular liquid. Ten dogs with CCLR, between male and female were enclosed on this study and they received a dose of 10mg/kg of tepoxalin daily. The lameness, arc movements test in maximum extension of the leg and digit pressure, as well as, the articular liquid analysis after 28 days of treatment, allow to conclude the effectiveness of the tepoxalin in the CCLR conservative treatment. It promoted the return to the normal deambulation in all treated cases, and it can be considerate one more option of AINE on the treatment of this artropathy.